Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immune System Therapeutics Ltd.
DescriptionHuman IgG1k chimeric mAb that induces antibody dependent cellular cytotoxicity (ADCC) through NK effector cells
Molecular Target Kappa myeloma antigen (KMA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation U.S. - Orphan Drug (Treat multiple myeloma (MM))
PartnerBristol-Myers Squibb Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today